InMed Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Feb 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2023 · Filed Feb 13, 2024

INM$15.56+17.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Interim Statements of Operations

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited)

For the Three Months Ended · For the Six Months Ended
December 31 · December 31
	Note	2023	2022	2023	2022
$ · $ · $ · $
Sales		1,240,200	469,783	2,142,062	790,571
Cost of sales		745,584	338,620	1,533,274	573,654
Inventory write-down	3	170,474	-	263,404	576,772
Gross profit		324,142	131,163	345,384	(359,855)
Operating Expenses
Research and development and patents		609,791	851,356	1,901,884	2,230,009
General and administrative		1,363,958	1,464,879	2,662,689	3,025,356
Amortization and depreciation	4, 5	55,234	49,049	110,066	98,097
Foreign exchange (gain) loss		(59,896)	(20,237)	(11,439)	76,554
Total operating expenses		1,969,087	2,345,047	4,663,200	5,430,016
Other Income (Expense)
Interest and other income		166,760	115,797	302,803	188,384
Loss before income taxes		(1,478,185)	(2,098,087)	(4,015,013)	(5,601,487)
Tax expense		-	(3,000)	-	(9,800)
Net loss for the period		(1,478,185)	(2,101,087)	(4,015,013)	(5,611,287)
Net loss per share for the period
Basic and diluted		(0.19)	(0.91)	(0.71)	(3.54)
Weighted average outstanding common shares
Basic and diluted		7,973,465	2,300,526	5,650,828	1,583,073

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.